Pipeline Comparison: Company vs Company
Compare pipelines on PoS-weighted forward NPV.
A structured way to compare pharma pipelines company-by-company — phase, modality, TA distribution and PoS-weighted forward NPV.
"Whose pipeline is structurally stronger — by what measure, in what TA?"
Asset-count comparisons mislead. PoS-weighted forward NPV across TA and modality reveals real strength differential.
Pipeline comparison decoupled from PoS-weighted NPV is theatre. Done right, it’s the most actionable BD and IC input strategy can produce.
What we’re seeing in the data.
Count ≠ value
50 P1s ≠ 5 P3s in NPV.
Concentration matters
TA-concentrated outperform diffuse.
Modality breadth signals platform
Vs opportunistic dealmaking.
How to think about it.
-
01
Build pipeline universe
All credible candidates per company.
-
02
Score per asset
PoS, launch, peak revenue.
-
03
Aggregate by TA
Forward NPV.
-
04
Compare across companies
Slice by modality, phase, geo.
What separates a good answer from a defensible one.
Limits realized launches.
Link asset NPVs.
Shapes effective revenue arc.
Where the signal comes from.
Common questions.
Why not analyst forecasts?
Often outdated within a quarter.
Granularity for BD?
Asset-level with explicit assumptions.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist